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Abstract
Background: Myelodysplastic syndrome (MDS) represents a group of clonal hematological disorders characterized
by progressive cytopenia, and reflects to defects in erythroid, myeloid and megakaryocytic maturation. MDS is
more frequently observed in older aged patients with cytogenetic abnormalities like monosomy of chromosome(s)
5 and/or 7. In 50% of de novo MDS cases, chromosomal aberrations are found and rearrangements involving the
retinoblastoma (RB1) gene in 13q14 are found.
Results: Here, we are presenting a case report of a rare biclonal MDS with a karyotype of 45, XY,-4, der(6)t(4;6)
(p15.1;p21.3), der(8)t(4;8)(q31.2;q22), t(13;16)(q21.3;p11.2)[11]/45, XY, der(7)t(7;13)(p22.2~22.3;q21.3),-13 [9]. The
patient was diagnosed according to WHO classification as refractory anemia with excess of blasts (RAEB-II).
Immunophenotyping was positive for CD11b, CD11c, CD10, CD13, CD15, CD16 and CD33.
Conclusion: We report, a novel and cytogenetically rare case of a biclonal MDS with complex chromosomal
aberrations and deletion of RB1-gene in both clones. These findings are associated with a poor prognosis as the
patient died 3 months after diagnosis.
Background
Myelodysplastic syndrome (MDS) refers to a group of
clonal acquired diseases characterized by trilineage
defects in erythrocytic, granulocytic, and megakaryocytic
lineages of hematopoiesis. Although considerable as a
clonal malignancy of its own, MDS is sometimes classi-
fied as a premalignant condition, which progresses to
acute myeloid leukemia (AML) regularly [1]. Overall,
MDS affects approximately 1 in 500 persons over 60
years of age, making it the most common hematologic
malignancy in this age group [1].
Cytogenetic abnormalities are found in ~50% of the
patients with de novo MDS and the most commonly
involved chromosomal changes observed are monosomy
5 and/or 7, trisomy 8 and/or partial deletion in 5q, 7q,
9q and 20q [2,3]. Unbalanced translocations are also fre-
quently found, and they are usually detected as a part of
complex karyotypes, associated with loss of chromoso-
mal material, and related to disease progression [4].
Deletions or translocations involving chromosomal
band 13q14, the locus of the retinoblastoma (RB1) gene,
are observed in a variety of hematological malignancies
including myelofibrosis (MF), MDS, AML, chronic mye-
logenous leukemia (CML) and chronic lymphocytic leu-
kemia (CLL) [4]. Recently, it has been shown that
deletions of 13q14 are detected at a high frequency
(more than 40%) in cases of CLL and multiple myeloma
(MM) by fluorescence in situ hybridization (FISH) ana-
lyses [4].
We are presenting a new case of a biclonal MDS case
with yet unreported translocation events involving six
different chromosomes and a monoallelic loss of RB1 in
both clones. In this case, multicolor banding (MCB)
technique was found very useful for characterizing the
breakpoints involved in the chromosomal rearrange-
ments in this case.
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In June 2009, a 60 year old male patient was referred with
anemia, thrombocytopenia, loss of weight and fever. His
white blood cell count was 7 × 10
9/l, with 64.5% neutro-
phils, 24.6% lymphocytes, 4.2% monocytes, 1% eosino-
philes, 1% basophils and 4.6% blast. Bone marrow was
hypercellular with 19% blast cells. Dysplastic changes in
bone marrow included cytoplasmic hypogranulation of
neutrophils, erythroblasts and micromegakaryocytes. The
red blood cell count was 3.38 × 10
6/cmm with 8.3 g/dl
hemoglobin level along with platelet count of 49 × 10
9/l,
and LDH value of 571 U/l. Physical examination of the
patient showed splenomegaly. The patient was treated
with Zyloric (300 mg as a daily dose) and Hydroxyurea
(500 mg as a daily dose) for 1 month and later continued
on Hydroxyurea (500 mg as a daily dose) for 3 month.
The patient died 3 months after diagnosis.
Karyotyping was done after the initiation of the treat-
ment which showed a mosaic and biclonal karyotype
with 45, XY, -4, der(6)t(4;6)(?;?), der(8)t(4;8)(?;?), t(13;16)
(?;?)/45, XY, der(7)t(7;13)(?;?),-13 (Figure 1), which was
further studied by molecular cytogenetics (Figure 2, 3,
4). Dual-color-FISH using WCP and CEP probes specific
for chromosomes 4, 6, 7, 8, 13 and 16 confirmed the
translocation seen in GTG-banding. Application of sub-
telomeric probes for 7pter and 7qter revealed two sig-
nals of subtelomeric 7qter on both homologous
chromosomes 7 and one signal of subtelomeric 7pter on
intact chromosome 7. Thus, subtelomeric region 7pter
was deleted on the derivative chromosome 7 (Figure 2).
Applying an RB1-specific probe showed one signal only
on the normal chromosome 13 in both clones. The ana-
lysis using MCB probes specific for individual chromo-
some involved in translocation, determined the
breakpoint location and the final karyotype was found
to be with 45, XY, -4, der(6)t(4;6)(p15.1;p21.3), der(8)t
(4;8)(q31.2;q22), t(13;16)(q21.3;p11.2)[11]/45, XY, der(7)t
(7;13)(p22.2~22.3;q21.3),-13 [9].
Immunophenotyping of peripheral blood characterized
the neutrophiles which showed abnormal side scatter
pattern, as well as abnormal intensity staining patterns
for CD11b(63%), CD11c(59.3%), CD10(17.4%), CD13
(44%), CD15(59.3%), CD16(46%) and CD33(20.4%). The
majority of monocytes were HLADr+ (4.2%). Lympho-
cyte subsets percentages were low. The patient was diag-
nosed as having common MDS, refractory anemia with
excess of blasts (RAEB) in the French-American-British
(FAB) classification, or RAEB-II in the World Health
Organization (WHO) classification [5].
Discussion
We described a biclonal MDS case with cytogenetic
rearrangements involving six different chromosomes
together with a monoallelic loss of the RB1 gene in both
clones.
The Cancer Genome Anatomy Project databases
(http://cgap.nci.nih.gov/Chromosomes/AbnCytSearch-
Form) and atlas of genetics and cytogenetics in oncology
and hematology (http://atlasgeneticsoncology.org/)
showed not a single case of MDS with a der(6)t(4;6)
(p15.1;p21.3), a der(7)t(7;13)(p22.2~22.3;q21.3), a der(8)t
(4;8)(q31.2;q22), or a t(13;16)(q21.3;p11.2). Contrarily
the involvement of RB1 gene in MDS is known and
appears to be a rare event [4]. The RB1 protein acts as a
cell cycle regulator which blocks the transition of nor-
mal cells from G0/G1 into S phase of the cycle. Mice
with homozygous disruption of the RB1 alleles resulted
in an overall normal development but had lethal anemia,
suggesting a critical role of the RB1 gene in erythropoi-
esis [4]. In the present case, anemia and thrombocytope-
nia were predominantly observed during the clinical
course, while white blood cells count was relatively pre-
served. This impaired erythropoiesis might be related to
monoallelic loss of the RB1 gene [4].
Besides imbalances of chromosomes 13, the observed
rearrangements lead to a partial monosomy 4p15.1 to
4q31.2 in the slightly larger of both clones. In accor-
dance with the international prognostic scoring system
(IPSS) classification of chromosomes 4 and 13 loss in a
RAEB-II stage patient supports an intermediate-2 prog-
nosis group and/or poor prognosis group [6,7].
The decreased heterogeneous expression of those anti-
gens was consistent with myelodysplastic disease in
transition.
Concerning the additional observed acquired imbal-
ances, up to present somehow similar minor terminal
deletions of 6p21.3 in malignant hematological disorders
was observed, and an involvement of the breakpoint
8q22 in an oncogene induced solid tumor [8,9]. Dele-
tions of 7p confer an inferior outcome in children with
ALL, regardless of the presence of other poor prognostic
features. Monosomy 7 is also associated with inferior
event-free survival (EFS) in children with ALL [10].
13q21.3 region was involved in CLL cases and 16p11.2
region was found in classical Hodgkin lymphoma but to
our knowledge our breakpoints have not been reported
in MDS, yet [11,12].
According to a recent study, the LDH level was nearly
as powerful as a prognostic parameter as karyotyping
and an elevated LDH was associated with poor prog-
nosis in MDS [13]. The LDH level for the presented
patient was 571 U/l, which compared to the normal
value (up to 480 U/l) is enhanced. Thus, also the LDH
l e v e la sw e l la sc y t o g e n e t i c ss u p p o r t e da na d v e r s ep r o g -
nosis, which unfortunately was confirmed by the clinical
outcome.
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involving six chromosomes distributed in two clones
and monoallelic loss of RB1 in both clones. Our finding
and according to WHO classification, IPSS and LDH is
considered to a poor prognostic factor in MDS patients,
as no response was observed after the application of
chemotherapy.
Materials and methods
Chromosome analysis
Chromosome analysis using GTG-banding was per-
formed according to standard procedures [14]. Twenty
metaphases derived from unstimulated bone marrow of
the patient were analyzed. Karyotypes were described
according to the International System for Human Cyto-
genetic Nomenclature [15].
Molecular cytogenetics
Fluorescence in situ hybridization (FISH) using whole
chromosome painting (WCP) probe for chromosomes 4,
6, 7, 13 and 16 (MetaSystems/Germany) and subtelo-
meric probes for 7pter and 7qter (Abbott Molecular/
Vysis, USA) were applied according to manufacturer’s
instructions together with a chromosome enumeration
Figure 1 GTG-banding revealed a biclonal condition in the present case. All derivative chromosomes are marked by an arrow head. (A) A
translocation between chromosomes 7, 13 and loss of one chromosome 13 was observed. (B) A complex karyotype involving the chromosomes
4, 6, 8, 13 and 16.
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RB1 (LSI 13 (RB1) Abbott Molecular/Vysis, USA) [14].
Multicolor banding probe (MCB) sets based on micro-
dissection derived region-specific libraries for chromo-
some 4, 7, 13 and 16 were applied as previously
described [16]. Twenty metaphase spreads were ana-
lyzed, each using a fluorescence microscope (AxioIma-
ger.Z1 mot, Zeiss) equipped with appropriate filter sets.
Image capturing and processing were carried out using
an Isis mFISH imaging system (MetaSystems, Altlus-
sheim, Germany).
Immunophenotyping
Immunophenotyping of leukemic blasts was done using
general panel of fluorescent antibodies against the fol-
lowing antigens typical for different cell lineages and
c e l lt y p e s :C D 1 a ,C D 2 ,C D 3 ,C D 4 ,C D 5 ,C D 8 ,C D 1 0 ,
CD11b, CD11c, CD13, CD14, CD15, CD16, CD19,
CD20, CD22, CD23, CD32, CD33, CD34, CD38, CD41a,
CD45, CD56, CD57, CD64, CD103, CD117, CD123,
CD209, CD235a and CD243; In addition to antibodies
to Kappa and Lambda light Chains, sIgD, sIgM, and
HLADr. All antibodies were product from BD
Figure 2 Karyotype and chromosomal aberrations were confirmed using molecular cytogenetic approach. (A) The translocation among
chromosomes 4, 6 and 8 were identified using WCP for chromosomes 4 and 6 (MetaSystems, Altlussheim, Germany) mixed with CEP 8 (Abbott
Molecular/Vysis, USA). (B) The translocation between chromosomes 7 and 13 was identified using WCP for chromosomes 7 and 13 (MetaSystems,
Altlussheim, Germany). (C) The translocation between chromosomes 13 and 16 was identified using WCP for chromosomes 13 and 16
(MetaSystems, Altlussheim, Germany). (D) The subtelomeric deletion of chromosome 7 was identified using subtelomeric 7pter and subtelomeric
7qter (Abbott Molecular/Vysis, USA). Abbreviations: #, chromosome; der, derivative chromosome.
Figure 3 Fluorescence in situ hybridization (FISH) using probe
for RB1 gene on metaphase spread showed one RB1 signal on
normal chromosome 13 in the second clone. Abbreviations: #,
chromosome.
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eral blood specimen was performed. Samples stained
a n da n a l y z e do naB DF A C S C a l i b u r ™ flow cytometer
according to BD Biosciences manuals and products
insert sheets. Autofluorescence, viability, and isotype
controls were included. Flow cytometric data acquisition
and analysis conducted by BD Cellquest™ Pro software.
Consent
Written informed consent was obtained from the patient
for publication of this case report and accompanying
images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
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